(HealthDay News) — Overactive bladder (OAB) is prevalent among women with fibromyalgia (FM) and is associated with higher symptom severity and comorbidity, according to a study published online Dec. 3 ...

A new study published in the journal of Neurourology and Urodynamics revealed a long-overlooked connection between ...

Summary • FibroBiologics, Inc. (FBLG) shares rose 16% in pre-market trading, reaching $0.2796 after funding news.• The company closed a $1.7 million offering, issuing 5,227,275 shares at $0.33 each to ...

FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and ...

A Newton-le-Willows father and husband has set up a local fibromyalgia support group after years of caring for his wife who lives with the condition.

Overactive bladder (OAB) is prevalent among women with fibromyalgia (FM) and is associated with higher symptom severity and ...

FibroGen has pulled the plug on its lead drug pamrevlumab after two failed trials in pancreatic cancer and immediately announced plans to shed three-quarters of its workforce. The San Francisco ...

Tonix Pharma is preparing to launch the first new therapy for fibromyalgia in the US in 16 years, after claiming FDA approval for Tonmya, an oral drug used to treat the pain associated with the ...

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan ...

Investing.com -- FibroGen, Inc. (NASDAQ:FGEN) stock rose 3% Monday after the company announced that its drug roxadustat received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA ...

Summary • FibroGen, Inc. shares surged 30% in pre-market trading, rising to $10.92 from $8.38.• The increase occurs without ...